[Concept for routine practice data collection for valoctocogene roxaparvovec acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 1.0) and the statistical analysis plan (Version1.0) – Second addendum to Commission A22-20]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005258
German
Original Title:
Anwendungsbegleitende Datenerhebung zu Valoctocogen Roxaparvovec: Prüfung des Studienprotokolls (Version 1.0) und des statistischen Analyseplans (Version 1.0) - 2. Addendum zum Projekt A22-20
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a23-64.html
Year Published:
2023
URL for published report:
https://www.iqwig.de/download/a23-64_valoctocogen-roxaparvovec_addendum-zum-projekt-a22-20_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Hemophilia A
- Antibodies, Bispecific
- Factor VIII
- Genetic Therapy
Keywords
- Valoctocogene Roxaparvovec
- Hemophilia A
- Benefit Assessment
- Registries
- Research Design
- Peer Review – Research
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.